TY  - JOUR

T1  - Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/106724/

PY  - 2016/08/01

AU  - Rafia R

AU  - Scope A

AU  - Harnan S

AU  - Stevens JW

AU  - Stevenson M

AU  - Lobo A

ED  - 

DO  - DOI: 10.1007/s40273-016-0436-6

VL  - 34

IS  - 12

SP  - 1241

EP  - 1253

Y2  - 2024/10/18

ER  -